Overview

A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Pfizer
Treatments:
Avibactam
Avibactam, ceftazidime drug combination
Ceftazidime
Meropenem
Thienamycins
Criteria
Inclusion Criteria:

- 18 to 90 years of age inclusive

- Females can participate if surgically sterile or completed menopause; if able to have
children, must have negative serum pregnancy test, agree not to attempt pregnancy and
use acceptable contraception while receiving study therapy and for 1 week after

- Onset of symptoms ≥ 48 hours after admission or <7 days after discharge from an
inpatient acute or chronic care facility

- New or worsening infiltrate on chest X-ray obtained within 48 hours prior to
randomization

- At least 1 of the following systemic signs:Fever (temperature >38 C) or hypothermia
(rectal/core temperature <35 C); White blood cell count >10,000 cells/mm3, or White
blood cell count <4500 cells/mm3, or >15% band forms.

Exclusion Criteria:

- Pulmonary disease that, in the investigator's judgment, would preclude evaluation of
therapeutic response (e.g. lung cancer, active tuberculosis, cystic fibrosis,
granulomatous disease, fungal pulmonary infection or recent pulmonary embolism).

- Patients with lung abscess, pleural empyema or post obstructive pneumonia.

- Patients with an estimated creatinine clearance <16ml/min by Cockcroft Gault formula
or patients expected to require haemodialysis or other renal support while on study
therapy.

- Acute hepatitis in the prior 6 months, cirrhosis, acute hepatic failure or acute
decompensation of chronic hepatic failure.

- Patients receiving hemodialysis or peritoneal dialysis.